Daniel Getts, PhD
Dr. Getts is the CEO and co-founder of Myeloid Therapeutics. Prior to Myeloid, he was the VP of Research at TCR2 (NASDAQ, TCRR) and a member of the leadership team that successfully guided the company through a series B ($120M) financing and an IPO (~$80M). Dr. Getts’s primary duties were to lead the company’s target discovery, preclinical, and translational research programs. These efforts resulted in numerous patent applications, a robust pipeline, and a successfully filed IND. Before TCR2, Dr. Getts was the primary inventor, founder, and Chief Scientific Officer of Cour Pharmaceuticals Development Company — a nanotechnology platform company focused on autoimmunity and inflammation. As a member of the company’s leadership team, he assisted in negotiating several pharmaceutical company collaborations and licenses, including Takeda, which ultimately licensed TIMP-GLIA for $420M plus royalties. Prior to Cour, Dr. Getts was the Director of Research & Development at Tolera Therapeutics. He served as the lead immunologist responsible for advancing the company’s monoclonal T-cell antibody program from discovery to Phase 3.
Dr. Getts has received numerous honors and awards, over 10 issued patents, and many more pending patent applications. He is widely published, including over 45 peer-reviewed publications with seminal publications in Nature Biotechnology, Science Translational Medicine, and Nature Communications. Dr. Getts completed his postdoctoral training at Northwestern University in Stephen D. Miller’s laboratory. He holds a PhD in Medicine from the University of Sydney and an MBA from Western Michigan University.